{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T21:29:50Z","timestamp":1771104590090,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1093017"],"award-info":[{"award-number":["APP1093017"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1141295"],"award-info":[{"award-number":["APP1141295"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","award":["700455"],"award-info":[{"award-number":["700455"]}],"id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In-transit metastases (ITMs) affect approximately 4% of patients with cutaneous melanoma. This study sought to identify clinical and pathological characteristics that predict further recurrence and survival following resection of ITMs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and Methods<\/jats:title>\n                <jats:p>Patients (<jats:italic>n<\/jats:italic> = 573) who underwent surgical resection of their first presentation of ITM following previous surgical treatment of an American Joint Committee on Cancer (AJCC) stage I\u2013II melanoma between 1969 and 2017 were identified from an institutional database. Clinicopathological predictors of patterns of recurrence and survival following ITM resection were sought.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median time of ITM development was 2.4 years after primary melanoma resection. ITMs were most frequently located on the lower limb (51.0%). The most common melanoma subtype associated with ITM development was nodular melanoma (44.1%). After surgical resection of a first ITM, 65.4% of patients experienced recurrent disease. Most recurrences were locoregional (44.7%), with distant metastasis occurring in 23.9% of patients. Lower limb ITMs were more frequently associated with subsequent ITMs [odds ratio (OR) 2.41, <jats:italic>p<\/jats:italic> = 0.0002], and the\u00a0lowest risk of distant metastasis (<jats:italic>p<\/jats:italic> &lt; 0.0001) compared with other primary sites. Primary melanomas and ITM on head and neck, as well as the\u00a0presence of ulceration, were associated with worse survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Recurrence after surgical resection of a first ITM was common. Patterns of recurrence differed according to anatomical site; further ITM recurrences were more likely for lower limb ITMs, which were also associated with longer distant recurrence-free survival. Distant metastasis was more common for ITM on the\u00a0head and neck, with worse survival.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-022-11997-0","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T15:08:42Z","timestamp":1656601722000},"page":"7019-7028","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases"],"prefix":"10.1245","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3811-2916","authenticated-orcid":false,"given":"Anna K.","family":"Lawless","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Coker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serigne N.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tasnia","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Scolyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sydney","family":"Ch\u2019ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omgo E.","family":"Nieweg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerwin","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Spillane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan R.","family":"Stretch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn P. M.","family":"Saw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"11997_CR1","doi-asserted-by":"crossref","unstructured":"Farley CR DK. Management of melanoma locoregional recurrence. In: Riker AI, editor. Melanoma: A Modern Multidisciplinary Approach Cham: Springer; 2018. pp 351\u20139.","DOI":"10.1007\/978-3-319-78310-9_20"},{"issue":"4","key":"11997_CR2","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/jso.20079","volume":"86","author":"U Leiter","year":"2004","unstructured":"Leiter U, Meier F, Schittek B, Garbe C. The natural course of cutaneous melanoma. J Surg Oncol. 2004;86(4):172\u20138.","journal-title":"J Surg Oncol."},{"issue":"7","key":"11997_CR3","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/jso.25400","volume":"119","author":"T Read","year":"2019","unstructured":"Read T, Lonne M, Sparks DS, David M, Wagels M, Schaider H, et al. A systematic review and meta-analysis of locoregional treatments for in-transit melanoma. J Surg Oncol. 2019;119(7):887\u201396.","journal-title":"J Surg Oncol."},{"issue":"2","key":"11997_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.soc.2014.12.008","volume":"24","author":"PJ Speicher","year":"2015","unstructured":"Speicher PJ, Meriwether CH, Tyler DS. Regional therapies for in-transit disease. Surg Oncol Clin N Am. 2015;24(2):309\u201322.","journal-title":"Surg Oncol Clin N Am."},{"key":"11997_CR5","doi-asserted-by":"crossref","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI et al. Melanoma staging evidence-based changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin., 2017;67(6):472-92.","DOI":"10.3322\/caac.21409"},{"issue":"13","key":"11997_CR6","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1056\/NEJMoa060992","volume":"355","author":"DL Morton","year":"2006","unstructured":"Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307\u201317.","journal-title":"N Engl J Med."},{"issue":"2","key":"11997_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1245\/s10434-014-4100-0","volume":"22","author":"RL Read","year":"2015","unstructured":"Read RL, Haydu L, Saw RP, Quinn MJ, Shannon K, Spillane AJ, et al. In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. Ann Surg Oncol. 2015;22(2):475\u201381.","journal-title":"Ann Surg Oncol."},{"key":"11997_CR8","unstructured":"Henderson MA. What are the most effective treatments of satellite and in-transit metastases? Cancer Council Australia. Available from: https:\/\/wiki.cancer.org.au\/australia\/Clinical_question:What_are_the_most_effective_treatments_for_satellite_and_in-transit_metastatic_melanoma%3F. Accessed 26 June 2022."},{"issue":"16","key":"11997_CR9","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622\u201334.","journal-title":"J Clin Oncol."},{"issue":"19","key":"11997_CR10","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789\u2013801.","journal-title":"N Engl J Med."},{"issue":"19","key":"11997_CR11","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, Atkinson V, Mandala M, Chiarion-Sileni V, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813\u201323.","journal-title":"N Engl J Med."},{"issue":"19","key":"11997_CR12","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824\u201335.","journal-title":"N Engl J Med."},{"issue":"11","key":"11997_CR13","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","volume":"24","author":"RN Amaria","year":"2018","unstructured":"Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018;24(11):1649\u201354.","journal-title":"Nat Med."},{"issue":"11","key":"11997_CR14","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","volume":"24","author":"CU Blank","year":"2018","unstructured":"Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24(11):1655\u201361.","journal-title":"Nat Med."},{"issue":"7","key":"11997_CR15","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","volume":"20","author":"EA Rozeman","year":"2019","unstructured":"Rozeman EA, Menzies AM, van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019;20(7):948\u201360.","journal-title":"Lancet Oncol."},{"issue":"3","key":"11997_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/DSS.0000000000001643","volume":"45","author":"DV Bann","year":"2019","unstructured":"Bann DV, Chaikhoutdinov I, Zhu J, Andrews G. Satellite and in-transit metastatic disease in melanoma skin cancer: a retrospective review of disease presentation, treatment, and outcomes. Dermatol Surg. 2019;45(3):371\u201380.","journal-title":"Dermatol Surg."},{"issue":"4","key":"11997_CR17","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/jso.25176","volume":"118","author":"AB Gonzalez","year":"2018","unstructured":"Gonzalez AB, Baum CL, Brewer JD, Arpey CJ, Harmsen WS, Suman VJ, et al. Patterns of failure following the excision of in-transit lesions in melanoma and the influence of excisional margins. J Surg Oncol. 2018;118(4):606\u201313.","journal-title":"J Surg Oncol."},{"issue":"2","key":"11997_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/jnci\/djq455","volume":"103","author":"Y Xing","year":"2011","unstructured":"Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011;103(2):129\u201342.","journal-title":"J Natl Cancer Inst."},{"issue":"4","key":"11997_CR19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/CMR.0000000000000666","volume":"30","author":"LHJ Holtkamp","year":"2020","unstructured":"Holtkamp LHJ, Chakera AH, Fung S, Stretch JR, Saw RPM, Lee K, et al. Staging 18F-FDG PET\/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases. Melanoma Res. 2020;30(4):358\u201363.","journal-title":"Melanoma Res."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-11997-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-11997-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-11997-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T15:20:22Z","timestamp":1663773622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-11997-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["11997"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-11997-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]},"assertion":[{"value":"25 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.A.S. has received fees for professional services from Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp and Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, GlaxoSmithKline, F. Hoffmann-La Roche. J.F.T. has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK and Provectus Inc, travel support from GSK and Provectus Inc and support for conference attendance from Novartis. R.P.M.S. has received honoraria for advisory board participation from MSD, Qbiotics, and Novartis and speaking honoraria from BMS and Novartis. A.K.L., D.J.C., S.N.L., T.A., S.C., O.E.N., K.S., A.S., and J.R.S. have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}